Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effects of OPRM1 118A>G on methadone response in pain management in advanced cancer at end of life.

Scientific reports - 10 Feb 2024

Haupt Larisa M, Haywood Alison, Sutherland Heidi G, Yu Chieh, Albury Cassie L, Pharasi Anushka, Zunk Mathew, George Rani, Griffiths Lyn R, Good Phillip, Hardy Janet

Abstract excerpt

Cancer pain is the most feared symptom at end of life. Methadone has advantages over other opioids but is associated with significant variability in clinical response, making dosing challenging in practice. OPRM1 is the most studied pharmacogene associated with the pharmacodynamics of opioids, however reports on the association of the A118G polymorphism on opioid dose requirements are conflicting, with no reports...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analgesics, Opioid
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Methadone

Share to Neoplasms

Share to Pain Management

Share to Polymorphism, Single Nucleotide

Share to Receptors, Opioid, mu

Source

Open in PubMed Open full text

Identifiers

PMID: 38341456
DOI: 10.1038/s41598-024-54009-9
PMCID: PMC10858860

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effects of OPRM1 118A>G on methadone response in pain management in advanced cancer at end of life.PMID 38341456Read ↗

OPRM1 c.118A>G Polymorphism and Duration of Morphine Treatment Associated with Morphine Doses and Quality-of-Life in Palliative Cancer Pain Settings.Semantic proximity Read ↗

Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement.Semantic proximity Read ↗

Association of polymorphisms in ARRB2 and clinical response to methadone for pain in advanced cancer.Semantic proximity Read ↗

Personalising pain management in advanced cancer: is KCNJ6 A1032G associated with methadone response?Semantic proximity Read ↗

Role of genetic polymorphisms on opioid safety and efficacy in cancer pain: A systematic review and meta-analysis.Semantic proximity Read ↗

Comparison of the Effects of OPRM1 A118G Polymorphism Using Different Opioids: A Prospective Study.Semantic proximity Read ↗

Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment.Semantic proximity Read ↗

Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene.Semantic proximity Read ↗

Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1.Semantic proximity Read ↗

Pharmacogenetics of Opioid ResponseSemantic proximity Read ↗

Genetics and Opioids: Towards More Appropriate Prescription in Cancer PainSemantic proximity Read ↗

Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.